Dr Elaine V. Jones
Member of the Board of Directors since 2021, US national
Accomplished biopharmaceutical executive with more than 20 years of life science investing experience. Vice President, Venture Capital, at Pfizer Ventures (2008-2019). General Partner with the venture fund, EuclidSR Partners (2003 - 2008) and Vice President at S.R. One, GlaxoSmithKline’s corporate fund (1999 - 2003). Previously, Director, Scientific Licensing for SmithKline Beecham and research scientist in SmithKline Beecham Pharmaceutical R&D. Ph.D. in Microbiology from the University of Pittsburgh and BS from Juniata College.
Chairwoman of the Board of Directors Gritstone bio (NASDAQ: GRTS) since 2020 and Mironid Ltd since 2019. Member of the Board of Directors CytomX Therapeutics (NASDAQ: CTMX) since 2019, NextCure (NASDAQ: NXTC) since 2016, Novartis Venture Fund since 2020, Ibere Pharmaceuticals (NYSE: IBER) since 2021 and Myeloid Therapeutics since 2021.